Denali Therapeutics

Denali Therapeutics

World Rank (Aug-2026)
4250
Market Cap (Aug-2026)
3.900 Billion USD
Market Cap (Mar-08-2026)
3.123 Billion USD
World Rank (Jan-05-2024)
4,587
Market Cap (Jan-05-2024)
2.812 Billion USD
World Rank (Jul-30-2023)
3,643
Market Cap (Jul-30-2023)
3.830 Billion USD
World Rank (Jan-07-2022)
3,242
Market Cap (Jan-07-2022)
5.076 Billion USD
World Rank (Jan-01-2021)
1,682
Market Cap (Jan-01-2021)
9.992 Billion USD
Headquarters Country
USA
Top Technology Companies in USA
Top Healthcare Companies in USA
Nasdaq / NYSE Code
DNLI
Employee Count
380
Employee Count as of Date
As on 2021
Headquarters City/State
California
World Region
Americas
World Subregion
Northern America
Annual Revenue in USD
0 Million USD
Annual Operating Income in USD
-555 Million USD
Annual Net Income in USD
-513 Million USD
Annual Results for Period Ending
For year ending December-2025
Total Assets in USD
1,145 Million USD
Total Liabilities in USD
131 Million USD
Total Equity in USD
1,014 Million USD
Balance Sheet for Period Ending
As of December-2025
Business Sector
Healthcare
Biotechnology
Technology
HealthCare Products
Company Website
DENALI THERAPEUTICS INC
Yahoo
Yahoo @ Nasdaq
Company Profile

Denali Therapeutics is a Biotechnology company focused on Neurodegenerative Diseases. The headquarters is in USA.

Annual Results Summary

DENALI THERAPEUTICS - Annual Results Summary - in Million USD

Year Ending:Total RevenueOperating IncomeNet Income
Dec-2022108-340 (Loss)-325 (Loss)
Dec-202148 -295 (Loss)-290 (Loss)
Dec-20203366271
Dec-201927213 (Loss)197 (Loss)
Dec-201812946 (Loss)36 (Loss)
Balance Sheet Summary

Total Assets as on Dec-2022 was 1,460 Million USD.

Total Liabilities as on Dec-2022 was 417 Million USD.

Total Equity as on Dec-2022 was 1,042 Million USD.

Founded Year
2013
IPO Year
2017
Stock Exchange
Nasdaq
Nasdaq Sector
Health Care
Nasdaq Industry
Biotechnology: Biological Products (No Diagnostic Substances)

Share